• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Coeptis Pharma Buys Elto Pharma for Phase II Parkinson’s Asset

Share:

December 3, 2018

Wexford, Pa.-based Coeptis Pharmaceuticals is buying New York-based Elto Pharma. Elto Pharma is a joint venture between Amarantus Bioscience Holdings and PsychoGenics.

Under the deal, Coeptis is acquiring all outstanding share of Elto. Financial details have not been disclosed.

Elto Pharma is developing eltoprazine, which is in Phase IIb clinical development for Parkinson’s disease levodopa-induced dyskinesias, or Parkinson’s LID.

“Eltoprazine will be a key long-term growth driver for Coeptis given its outstanding profile as a potential therapy across several brain-related conditions,” stated David Mehalick, president and chief executive officer of Coeptis. “As we focus on the near-term commercialization of our 505(b)2 and generic pipeline, with the launch of our first FDA-approved 505(b)2 product expected in 2019, Coeptis will be strongly positioned to successfully launch its products across multiple disease areas in the years ahead. Eltoprazine has a blockbuster potential as a new chemical entity treatment for multiple neurological conditions, beginning with Parkinson’s LID.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Eltoprazine was first developed by Solvay, now AbbVie, for aggression-related indications. It was then out-licensed to PsychoGenics, which then licensed it to Amarantus in 2014. In April 2017, Amarantus incorporated the wholly-owned Elto Pharma in order to raise capital for clinical development of eltoprazine.

Earlier this month, Coeptis signed a multi-product agreement with Mumbai, India’s Ciron Drugs & Pharmaceuticals. Under that deal, the two companies will develop and commercialize several generic drugs. Ciron will develop and manufacture several drugs exclusively for Coeptis to market in the U.S. under its label. According to IMS Health, the drugs have a total U.S. sales of more than $100 million.

“We are very excited to partner with such an honorable company,” stated Dan Yerace, vice president of Operations at Coeptis. “Ciron’s business and personal integrity is world-class, and its commitment to manufacturing high-quality products has earned them a reputation of excellence. Partners like Ciron will play a vital role as Coeptis continues to expand its pipeline of niche, high-value products.”

Amarantus describes itself as “a U.S.-based, JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries.”

In June, it updated plans to raise capital for Elto Pharma. An independent third-party valuation valued eltoprazine in the U.S. and Europe at $316 million. At that time, Amarantus had two pathways for Elto. The first was standalone private funding followed by an initial public offering in the U.S. or Hong Kong. The second was a business combination with an established clinical-stage pharma company where Amarantus could become a significant shareholder.

At the time, Gerald E. Commissiong, president and chief executive officer of Amarantus and interim-chief executive officer of Elto, stated, “The immediate focus for Amarantus with regards to our wholly-owned subsidiary Elto Pharma is to ensure that we maximize the current value inherent in the eltoprazine asset, where a recent independent third-party valuation places the value of eltoprazine in PD-LID alone in the U.S. and Europe at approximately 30x the entire current market capitalization of Amarantus.”

He went on to say, “With the capital restructuring of Amarantus nearing its final stages, we believe we will soon be positioned to properly execute upon our Elto Pharma strategy. Ultimately, we see value not only from the PD-LID orphan indication for eltoprazine, which we expect to appreciate significantly over time as the PID-LID indication is further clinically de-risked, but we also intend to see the Agitation in Alzheimer’s disease and Adult ADHD indications for eltoprazine become valued by the market as Elto Pharma executes upon its clinical development strategy.”

Date: December 3, 2018

Source: PharmaLive

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • How AR and MR Technology Can Reduce Medical Vulnerability to Improve the Patient ExperienceHow AR and MR Technology Can Reduce Medical Vulnerability to Improve the Patient Experience
  • Using the 3M’s to Get Physicians to Embrace Telehealth: Metrics, Money eMotionUsing the 3M’s to Get Physicians to Embrace Telehealth: Metrics, Money eMotion
  • G1 Therapeutics Announces Pricing of Offering of Common Stock – November 18, 2022G1 Therapeutics Announces Pricing of Offering of Common Stock – November 18, 2022
  • Philips Launches Integrated Cybersecurity Services to Protect Connected Medical DevicesPhilips Launches Integrated Cybersecurity Services to Protect Connected Medical Devices
  • NeuroFlow, Atlantic Health System Partner to Launch Collaborative Care ModelNeuroFlow, Atlantic Health System Partner to Launch Collaborative Care Model
  • FCC Approves Third Set of 6 COVID-19 Telehealth Program ProvidersFCC Approves Third Set of 6 COVID-19 Telehealth Program Providers
  • Astellas Buys Audentes for $3 Billion to Expand Into Gene TherapyAstellas Buys Audentes for $3 Billion to Expand Into Gene Therapy
  • Mark Cuban Cost Plus Drug Company Announces Two Partnerships.Mark Cuban Cost Plus Drug Company Announces Two Partnerships.

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications